About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
The company’s lead product candidate, pegozafermin (BIO89-100), is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company believes that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as MASH and SHTG.
Funding history · 1 round · $1.1B total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was 89bio acquired and by whom?
- 89bio was acquired by Roche in September 2025.
- What was the total value of the Roche buyout deal for 89bio?
- In September 2025, 89bio shareholders were set to receive up to $3.5 billion total in the Roche buyout deal, with an immediate payment of $2.4 billion and an option for additional revenues.
- What is 89bio's lead product candidate and what conditions is it being evaluated for?
- 89bio's lead product candidate is pegozafermin (BIO89-100), an investigational glycopegylated FGF21 analog. It is currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
- When did 89bio initiate its Phase 3 ENLIGHTEN-Fibrosis trial?
- In March 2024, 89bio initiated its Phase 3 ENLIGHTEN-Fibrosis trial of pegozafermin in non-cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) patients with fibrosis.
- What significant regulatory status did 89bio receive for pegozafermin in March 2024?
- In March 2024, 89bio received EMA PRIME Status for pegozafermin for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with fibrosis and compensated cirrhosis.
- What was the outcome of 89bio's Phase 2b ENLIVEN trial of Pegozafermin in NASH patients?
- In March 2023, 89bio's Phase 2b ENLIVEN trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) achieved high statistical significance on both primary histology endpoints with weekly (QW) and every-two-week (Q2W) dosing at 24 weeks.
- When did 89bio announce the closing of its public offering and full exercise of underwriters’ option to purchase additional shares?
- In February 2025, 89bio announced the closing of its public offering and the full exercise of underwriters’ option to purchase additional shares.
- Who were the lead investors in 89bio's Series A funding round?
- 89bio's Series A funding round in October 2018 included RA Capital Management, Pontifax, OrbiMed, and Longitude Capital as investors.
- When did 89bio receive Breakthrough Therapy Designation from the U.S. FDA for Pegozafermin?
- In September 2023, 89bio announced that the U.S. FDA granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH).